Where Trackless Terrain Once Challenged Biomarker...
Where Does Your Region Stack Up...
Standardized Assays Are Driving Preemptive Genotyping...
Immunoassays Are Incorporating Brighter Signals and...
Biotechnology equipment spells big bucks for the industry’s top CEOs. [© ALYUSHIN - Fotolia.com]
Olivier A. Filliol, President and CEO
2011 Compensation: $5,379,639
2010 Compensation: $5,393,903
% Change: -0.3%
Marc N. Casper, President and CEO
2011 Compensation: $5,516,567
2010 Compensation: $2,761,689
% Change: 99.8%
Jay T. Flatley, President, CEO and Director
2011 Compensation: $9,944,147
2010 Compensation: $6,608,974
% Change: 50.5%
Edward J. Ludwig, Chairman and CEO
2011 Compensation: $10,091,273
2010 Compensation: $10,005,022
% Change: 0.9%
William P. Sullivan, President and CEO
2011 Compensation: $10,252,264
2010 Compensation: $10,442,447
% Change: -1.8%
Gregory T. Lucier, Chairman and CEO
2011 Compensation: $10,897,630
2010 Compensation: $11,498,009
% Change: -5.2%
Robert F. Friel, Chairman and CEO
2011 Compensation: $12,819,181
2010 Compensation: $7,948,297
% Change: 61.3%
Leave a comment by clicking the “Comments” icon. We want to hear your thoughts!
One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?
Be sure to add [email protected]
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2016 Genetic Engineering & Biotechnology News All Rights Reserved